uniQure N.V. (QURE)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
uniQure N.V. (QURE) trades at $41.30 with AI Score 45/100 (Grade C). uniQure N. V. is a gene therapy company focused on developing treatments for genetic diseases. Market cap: $2.81B, Sector: Healthcare.
Price live · AI analysis from May 10, 2026QURE stock analysis for 2026: Analysts have set a consensus price target of $30.33 for uniQure N.V., suggesting 26.6% downside from the current price of $41.30. The AI MoonshotScore is 45/100, indicating a neutral outlook. Key factors: analyst coverage, AI-driven quantitative scoring.
QURE: the 1 perspectives are evenly split.
How is this calculated? →uniQure N.V. (QURE) Healthcare & Pipeline Overview
uniQure N.V. is a gene therapy company specializing in the development of innovative treatments for genetic and other devastating diseases. Their pipeline includes programs targeting hemophilia B, Huntington's disease, Parkinson's disease, and Alzheimer's disease, positioning them as a key player in the rapidly evolving gene therapy market.
What Is the Investment Thesis for QURE?
uniQure presents a notable research candidate within the gene therapy space. The company's lead program, Etranacogene dezaparvovec (AMT-061), nearing potential market approval for hemophilia B, could generate substantial revenue. Positive Phase III trial results and subsequent regulatory approvals are key catalysts. The company's diversified pipeline, targeting diseases like Huntington's and Parkinson's, offers long-term growth potential. However, high R&D costs, regulatory hurdles, and competition from other gene therapy companies pose risks. With a market capitalization of $2.81B and a negative profit margin of -1154.4%, uniQure's future success hinges on successful commercialization and pipeline advancement.
Based on FMP financials and quantitative analysis
QURE Key Highlights
- Market capitalization of $2.81B reflects investor confidence in uniQure's gene therapy pipeline.
- Gross margin of 57.8% indicates strong potential profitability upon commercialization of its therapies.
- Etranacogene dezaparvovec (AMT-061) in Phase III HOPE-B pivotal trial represents a near-term catalyst for potential revenue generation.
- Pipeline includes programs targeting Huntington's disease, Parkinson's disease, and Alzheimer's disease, offering long-term growth opportunities.
- Beta of 0.75 suggests lower volatility compared to the overall market.
Who Are QURE's Competitors?
QURE is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| EWTX Edgewise Therapeutics, Inc. | $40.10 | +1.37% | $4.31B | 69 |
| SNDX Syndax Pharmaceuticals, Inc. | $22.11 | +1.33% | $1.96B | 79 |
| ANAB AnaptysBio, Inc. | $63.69 | +0.43% | $2.75B | 79 |
| CGEN Compugen Ltd. | $2.37 | +3.73% | $223.62M | 76 |
| XFOR X4 Pharmaceuticals, Inc. | $4.09 | -0.86% | $386.20M | 76 |
| DAWN Day One Biopharmaceuticals, Inc. | $21.53 | +0.00% | $2.22B | 68 |
| GLUE Monte Rosa Therapeutics, Inc. | $23.06 | -4.75% | $1.50B | 68 |
| RNAM Avidity Biosciences Inc | $72.86 | +0.05% | $11.26B | 68 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are QURE's Key Strengths?
- Proprietary AAV gene therapy platform.
- Advanced clinical pipeline.
- Experienced management team.
- Strong intellectual property position.
What Are QURE's Weaknesses?
- High R&D costs.
- Dependence on clinical trial outcomes.
- Regulatory hurdles.
- Limited commercialization experience.
What Could Drive QURE Stock Higher?
- Etranacogene dezaparvovec (AMT-061) regulatory approval decisions for hemophilia B.
- Clinical data updates from the AMT-130 program for Huntington's disease.
- Enrollment and data readouts from ongoing clinical trials.
- Potential new partnerships and collaborations.
What Are the Key Risks for QURE?
- Financial-distress signal — its Altman Z-Score of 0.50 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
- Insider selling — insiders were net sellers of roughly $9.3M recently.
- Adverse clinical trial results.
- Regulatory delays or rejections.
- Competition from other gene therapy companies.
- High R&D expenses.
- Manufacturing challenges.
What Are the Growth Opportunities for QURE?
- Etranacogene dezaparvovec (AMT-061) Commercialization: The successful completion of the Phase III HOPE-B trial and subsequent regulatory approval for Etranacogene dezaparvovec (AMT-061) represents a significant growth opportunity. The hemophilia B market is estimated to be worth billions of dollars, and uniQure could capture a substantial share with a successful gene therapy product. Timeline: Potential market launch within the next 1-2 years, pending regulatory approvals.
- Expansion of Huntington's Disease Program (AMT-130): The AMT-130 program for Huntington's disease is currently in Phase I/II clinical trials. Positive clinical data and subsequent advancement to later-stage trials could unlock a significant market opportunity. Huntington's disease is a debilitating neurodegenerative disorder with limited treatment options. Timeline: Clinical data updates expected in the next 12-18 months.
- Advancement of Parkinson's Disease Program (AMT-210): uniQure's AMT-210 program targets Parkinson's disease, another major neurodegenerative disorder. Preclinical and early clinical data will be crucial for determining the program's potential. The Parkinson's disease market is substantial, with a growing need for effective therapies. Timeline: Early-stage clinical trials ongoing, with potential for advancement in the next 2-3 years.
- Development of Alzheimer's Disease Program (AMT-240): The AMT-240 program focuses on autosomal dominant Alzheimer's disease. While still in the preclinical stage, successful development could address a significant unmet medical need. The Alzheimer's disease market is one of the largest in the pharmaceutical industry. Timeline: Preclinical studies ongoing, with potential for clinical trials in the next 3-4 years.
- Strategic Partnerships and Collaborations: uniQure can pursue strategic partnerships and collaborations with larger pharmaceutical companies to accelerate the development and commercialization of its gene therapy programs. These partnerships can provide access to funding, expertise, and global market reach. Timeline: Ongoing, with potential for new partnerships to be announced in the near future.
What Opportunities Does QURE Have?
- Expanding gene therapy market.
- Strategic partnerships.
- New disease targets.
- Technological advancements in gene therapy.
What Threats Does QURE Face?
- Competition from other gene therapy companies.
- Adverse clinical trial results.
- Regulatory setbacks.
- Pricing and reimbursement challenges.
What Are QURE's Competitive Advantages?
- Proprietary AAV gene therapy platform.
- Strong intellectual property portfolio.
- Expertise in gene therapy development and manufacturing.
- First-mover advantage in certain disease areas.
What Does QURE Do?
Founded in 1998 and headquartered in Amsterdam, the Netherlands, uniQure N.V. is a pioneering gene therapy company dedicated to transforming the lives of patients suffering from genetic and other severe diseases. The company's mission is to develop and deliver innovative gene therapies that address unmet medical needs. uniQure's lead program, Etranacogene dezaparvovec (AMT-061), is currently in Phase III clinical trials (HOPE-B pivotal trial) for the treatment of hemophilia B, a genetic bleeding disorder. Beyond hemophilia B, uniQure is also developing a pipeline of gene therapy candidates targeting other debilitating conditions, including Huntington's disease (AMT-130, Phase I/II), Parkinson's disease (AMT-210), temporal lobe epilepsy (AMT-260), autosomal dominant Alzheimer's disease (AMT-240), and amyotrophic lateral sclerosis (AMT-161). uniQure leverages its proprietary AAV (adeno-associated virus) gene therapy platform to deliver therapeutic genes directly to target cells, offering the potential for long-lasting or even curative treatment outcomes. The company's focus on innovative gene therapy solutions positions it as a significant player in the biotechnology industry, with the potential to address a wide range of genetic disorders.
What Products and Services Does QURE Offer?
- Develop gene therapies for genetic diseases.
- Focus on adeno-associated virus (AAV) gene therapy platform.
- Lead program targets hemophilia B (Etranacogene dezaparvovec).
- Develop therapies for Huntington's disease, Parkinson's disease and Alzheimer's disease.
- Conduct clinical trials to evaluate the safety and efficacy of gene therapies.
- Seek regulatory approvals for gene therapy products.
- Commercialize gene therapies upon regulatory approval.
How Does QURE Make Money?
- Develop proprietary gene therapy products.
- Out-license or co-develop gene therapies with pharmaceutical partners.
- Generate revenue through product sales upon regulatory approval.
- Receive milestone payments and royalties from partnered programs.
What Industry Does QURE Operate In?
The biotechnology industry is experiencing rapid growth, driven by advancements in gene therapy and personalized medicine. The market for gene therapies is projected to reach billions of dollars in the coming years. uniQure operates in a competitive landscape with companies like EWTX: Edgewise Therapeutics, Inc. and others developing gene therapies for various genetic disorders. The success of uniQure depends on its ability to navigate regulatory hurdles, secure partnerships, and effectively commercialize its products.
Who Are QURE's Key Customers?
- Patients suffering from genetic diseases.
- Healthcare providers who treat patients with genetic diseases.
- Pharmaceutical companies seeking to partner on gene therapy development.
- Payers (insurance companies and government healthcare programs) who reimburse for gene therapy treatments.
Net sellingInsider Activity
Over the past six months, uniQure N.V. insiders filed 15 SEC Form 4 transactions — 11 sales and 4 purchases. On net that is roughly 200K shares disposed (about $9.3M), a signal worth weighing alongside the fundamentals.
QURE Valuation & Market Position
With a $2.81B market cap, uniQure N.V. sits in the mid-cap segment of the market. Relative to its peer group, QURE's quantitative score of 45/100 is below the peer average of 76/100.
Key Financial Metrics
Return on assets is -26.8%, showing how much profit it generates from its asset base. Its free cash flow yield is -5.6%, a gauge of the cash the business throws off relative to its market value. A current ratio of 10.40 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -6.8%, the inverse of the P/E and a quick read on earnings relative to price.
F-Score 3/9Financial Health
uniQure N.V.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 0.50 places it in the distress zone, a signal of elevated financial risk.
FY2026 estForward Outlook
Wall Street analysts project uniQure N.V. revenue of about $21.0M for fiscal 2026, with EPS near $-3.68. The estimate reflects 9 contributing analysts.
Company Profile
uniQure N.V. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Amsterdam, NL. The company is led by CEO Matthew Kapusta. QURE has traded publicly since 2014.
QURE Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Recent insider buying signals confidence in the company's future, indicating that management believes in upcoming positive developments.
- Community sentiment has shifted positively as recent updates on gene therapy advancements have sparked renewed interest among investors.
- Analysts are optimistic about the potential of uniQure's pipeline, particularly in rare diseases, which has garnered attention from the biotech community.
- The growing public awareness and acceptance of gene therapies is creating a favorable market environment for uniQure's innovations.
Bear Case
- Concerns over regulatory hurdles remain prevalent, as the biotech sector faces increased scrutiny from health authorities which could delay product launches.
- Recent discussions in community forums reveal skepticism regarding the scalability of uniQure's treatments, raising doubts about long-term profitability.
- Market perception has been tempered by broader economic uncertainties, leading to cautious sentiment among investors in the biotech space.
- Insider selling activity in previous months has raised red flags for some investors, causing hesitation about the company's immediate prospects.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · April 2026
QURE Latest News
-
Applied Materials To Rally Around 20%? Here Are 10 Top Analyst Forecasts For Monday
benzinga · Jun 29, 2026
-
What's Going On With Capricor Therapeutics Stock On Friday?
benzinga · Jun 26, 2026
-
Backblaze, Infleqtion, Zeta Global And Other Big Stocks Moving Higher On Tuesday
benzinga · Jun 23, 2026
-
12 Health Care Stocks Moving In Wednesday's Intraday Session
benzinga · Jun 17, 2026
QURE Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for QURE.
Price Targets
Consensus target: $30.33
QURE MoonshotScore
What does this score mean?
The MoonshotScore rates QURE's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Latest News
Applied Materials To Rally Around 20%? Here Are 10 Top Analyst Forecasts For Monday
What's Going On With Capricor Therapeutics Stock On Friday?
Backblaze, Infleqtion, Zeta Global And Other Big Stocks Moving Higher On Tuesday
12 Health Care Stocks Moving In Wednesday's Intraday Session
Latest uniQure N.V. Analysis
Leadership: Matthew Craig Kapusta
CEO
Matthew Craig Kapusta serves as the Chief Executive Officer of uniQure N.V. His career spans various leadership roles within the biopharmaceutical industry. Prior to joining uniQure, Kapusta held significant positions at companies focused on rare diseases and gene therapy. His experience includes strategic planning, business development, and commercial operations. He brings a wealth of knowledge in navigating the complexities of the biotechnology sector, particularly in the development and commercialization of innovative therapies.
Track Record: Under Kapusta's leadership, uniQure has focused on advancing its gene therapy pipeline, particularly Etranacogene dezaparvovec (AMT-061) for hemophilia B. Key achievements include the progression of AMT-061 through Phase III clinical trials and the continued development of programs targeting Huntington's disease and other neurological disorders. His strategic decisions have shaped the company's focus on innovative gene therapy solutions.
uniQure N.V. Healthcare Stock: Key Questions Answered
What does uniQure N.V. do?
uniQure N.V. is a gene therapy company focused on developing and commercializing innovative treatments for genetic diseases. The company's core technology involves using adeno-associated virus (AAV) vectors to deliver therapeutic genes directly to target cells. Its lead program, Etranacogene dezaparvovec (AMT-061), is designed to provide a one-time treatment for hemophilia B by delivering a functional gene to produce Factor IX, a clotting protein. Beyond hemophilia B, uniQure is developing a pipeline of gene therapies targeting other debilitating diseases, including Huntington's disease and Parkinson's disease, aiming to transform the lives of patients with limited treatment options.
What do analysts say about QURE stock?
Analyst consensus on QURE stock reflects the potential of its gene therapy pipeline, particularly Etranacogene dezaparvovec (AMT-061) for hemophilia B. Key valuation metrics include projected revenue from potential product sales and the overall market opportunity for gene therapies. Growth considerations center on the successful completion of clinical trials, regulatory approvals, and commercialization efforts. Analysts also monitor the progress of uniQure's other pipeline programs and potential partnerships. The stock's performance is closely tied to clinical trial outcomes and regulatory milestones.
What are the main risks for QURE?
The main risks for uniQure N.V. include the inherent uncertainties associated with clinical trials and regulatory approvals. Adverse clinical trial results or regulatory setbacks could significantly impact the company's prospects. Competition from other gene therapy companies and the emergence of alternative treatments also pose risks. Additionally, the high costs of research and development and the challenges of manufacturing gene therapies on a commercial scale could affect uniQure's financial performance. Pricing and reimbursement challenges for gene therapies represent another potential risk factor.
What are the key factors to evaluate for QURE?
uniQure N.V. (QURE) holds an AI score of 45/100 (low). Analysts target $30.33 (-27%). Not financial advice.
How frequently does QURE data refresh on this page?
QURE prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven QURE's recent stock price performance?
uniQure N.V. (QURE) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary AAV gene therapy platform. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider QURE overvalued or undervalued right now?
Valuing uniQure N.V. (QURE) requires multiple metrics. Analysts target $30.33 (-27%) — downside risk seen. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying QURE?
Before investing in uniQure N.V. (QURE), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data and may be subject to change.
- Clinical trial outcomes are inherently uncertain.